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Antioxidants are widely considered as
being essential for an optimal health
so that supplementation with natural
antioxidants is advised for cancer, car-
diovascular diseases and other various
pathologies, whereas supplementation
with vitamin pills may not be advised,
as discussed below. By clicking “antiox-
idant miracle” on a web search engine
one gets about 2 million results. This
mainly relates to vitamin E and C, the
former being lipid-soluble and the latter
being water-soluble, which are best known
by laypeople. Antioxidants neutralize
the harmful effects of excessive forma-
tion of reactive oxygen species (ROS)
(Godfraind, 2004). They share this qual-
ity with major therapeutic agents such
as dihydropyridine-type calcium channel
blockers (Godfraind, 2004) that are estab-
lished drugs for treating cardiovascular
diseases. In this opinion paper, we intend
to compare some cardiovascular outcomes
of dietary antioxidant supplements versus
calcium channel blockers (CCBs).
Both clinical and experimental
evidences indicate that ROS play an
important role in the development of sev-
eral diseases including cancer (Chandel
and Tuveson, 2014) and hypertension
(Godfraind, 2004). The mitochondrial
electron transport chain and NADPH
oxidases (NOXs) localized to the plasma
membrane and the membrane of cellu-
lar organelles are producers of reactive
oxygen species. NOXs enzymes are a
family of heme-containing transmem-
brane proteins (Bedard and Krause, 2007).
These enzymes transport electrons across
the membrane from a cytosolic electron
donor to an electron acceptor located in
the extracellular or in the luminal space.
NADPH serves as electron donor and oxy-
gen as electron acceptor for the production
of reactive oxygen species (Bedard and
Krause, 2007). ROS comprise superoxide
anion (O2·−), hydroxyl radical (HO·), per-
oxyl radical (RO·2), alkoxyl radical (RO·)
(Dunford, 1987).
The highly reactive hydroxyl radical
can react with molecules in cells, includ-
ing DNA, proteins and lipids (Girotti,
1998). In the process of peroxidation,
hydroxyl radical reaction with phospho-
lipids is forming water (Girotti, 1998). For
example, assuming that LH represents the
lipid and OH· the hydroxyl radical (the ·
representing an electron):
LH + OH· → L· + H2O.
The lipid radical (L·) can then propagate
a chain of reactions causing breakdown of
a number of phospholipids and so dam-
aging cell membrane and cellular function
(Girotti, 1998). Endogenous antioxidants
(e.g., glutathione) and antioxidant vita-
mins (e.g., vitamin E) have been shown
to stop these reactions (Girotti, 1998).
Therefore, they may prevent peroxidative
damage to membranes and other cellu-
lar molecules, including proteins and DNA
(Girotti, 1998; Jialal et al., 2002).
When considering the cardiovascu-
lar system, excess production and/or
impaired break-down of O2·−, as well
as a decrease in NO bioactivity pro-
duce oxidative stress (Mangge et al.,
2014). Among consequences, one observes
decreased NO bioavailability in the vascu-
lature, stroke and cardiovascular remodel-
ing. In human hypertension, biomarkers
of systemic oxidative stress are elevated
(Redon et al., 2003). Among biomarkers,
ROS may be directly measured by electron
spin resonance, thiobarbituric acid reac-
tive substances (TBARS) may be assessed
by colorimetric or fluorometric meth-
ods, other biomarkers may be assessed by
ELISA.
Agents exerting antioxidant activity
comprise two major classes: enzymes and
scavengers. Antioxidants enzymes consist
of superoxide dismutase (SOD), catalase
and glutathione peroxidase. Dismutation
of O2·− by SOD produces H2O2 a more
stable ROS, which in turn is converted into
H2O by catalase and glutathione perox-
idase (de Haan et al., 1992). Scavengers
react with ROS, preventing the oxidation
reaction from continuing. Among scav-
engers listed in Box (Godfraind, 2004)
the most used as dietary supplements
and the most studied are vitamins E
and C. According to several authors
the antioxidant properties of CCBs may
be attributed either to direct scavenging
effect or to preservation of the activ-
ity of superoxide dismutase. It has been
experimentally shown that some CCBs
may inhibit oxidative damage to lipids
associated with cellular membranes and
lipoprotein particles. Under controlled
experimental conditions, they may inhibit
lipid peroxide formation at concentrations
as low as 10.0 nM, an effect indepen-
dent of calcium channel modulation. This
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antioxidant activity has been reported with
high lipophilic CCBs (Mason et al., 1993;
Godfraind, 2005) when their chemical
structure facilitates proton-donating and
resonance-stabilization mechanisms that
quench the free radical reaction. When
inserted into a location in the membrane
near polyunsaturated fatty acids, the CCBs
amlodipine and lacidipine donate protons
to lipid peroxidemolecules, thereby reduc-
ing the accumulation of peroxides. The
remaining unpaired free electron associ-
ated with the CCB molecule can be stabi-
lized in well-defined resonance structures
linked with the dihydropyridine ring of the
CCBmolecule. The reaction that describes
the antioxidant effects of a dihydropy-
ridine (DHP) CCB is as follows, where
LOO· represents a lipid peroxide molecule
(Godfraind, 2004):
LOO· + DHP → LOOH + DHP·
The use of dietary supplementation with
antioxidants has been studied in several
diseases, including cancer and cardiovas-
cular pathologies. As far as cancer is con-
cerned, as pointed out by Chandel and
Tuveson in a recent commentary (Chandel
and Tuveson, 2014), ROS both acceler-
ate and delay cancer initiation and pro-
gression (Chandel and Tuveson, 2014).
These authors explained these conflict-
ing outcomes as related to the mul-
tiple roles that ROS play during the
evolution of cancer cells and to their
site of action. ROS can promote cancer
by oxidizing specific intracellular chem-
ical moieties, resulting in genetic muta-
tions and/or activation of biochemical
pathways that stimulate proliferation and
neoplastic transformation (Chandel and
Tuveson, 2014). On the other hand, the
therapeutic effect of ionizing radiation
and of many common chemotherapeutic
drugs in the treatment of cancer depends
on the cytotoxic action of ROS. Chandel
and Tuveson (2014) proposed that this
dual action could result from whether or
not the site of action of ROS is distant
from mitochondria. ROS specifically oxi-
dize certain spatially collocated proteins
to activate a variety of cancer-stimulating
signaling pathways (Chandel and Tuveson,
2014). Distant from the mitochondria and
NADPH oxidases, ROS nonspecifically
damage macromolecules (DNA, RNA,
lipids, and proteins) and are toxic to both
normal and cancer cells (Chandel and
Tuveson, 2014). Dietary antioxidants neu-
tralize excess of reactive oxygen species at
distance of the site of their production
while leaving unperturbed the generated
tumorigenic ROS (Chandel and Tuveson,
2014). Accordingly, their pharmacologi-
cal effect might be anti- or pro-cancer
development.
Human studies have shown that, in
acute conditions (Donato et al., 2010),
a cocktail of antioxidant vitamins and
α-lipoic acid (AOC: vitamins C, E and α-
lipoic acid) restored the attenuated vasodi-
latation due to handgrip exercise in old
subjects, in agreement with reduced blood
venous levels of lipid peroxide (Donato
et al., 2010). But AOC had a different
effect in young and trained old subjects,
wherein it reduced the handgrip exer-
cise induced vasodilatation despite the
AOC reduction in free radicals (Donato
et al., 2010). According to the authors of
this report, their observation suggests that
exercise training in older subjects alters
the balance between pro- and antioxi-
dant forces, resulting in a greater reliance
on handgrip-mediated vasodilation in the
exercise-trained state (Donato et al., 2010).
This indicates that free radicals efficacy
might be affected by local processes within
the tissue, when comparing physiological
responses to a same exercise in a given
vascular territory.
Animal studies have shown that treat-
ment with superoxide dismutase (SOD)
mimetics or antioxidants, according
to the drug dosage, improves vascular
FIGURE 1 | Prolongation of survival in salt-loaded, stroke-prone spontaneously hypertensive
rats (SHR-SP) with high mortality due to malignant hypertension by CCBs or vitamin E
(redrawn from Napoli et al., 1999).
and renal function, regresses vascular
remodeling, and reduces blood pres-
sure (Godfraind, 2005). Stroke is one
of the most harmful complications of
hypertension (Moskowitz et al., 2010).
Studies comparing two strains of hyper-
tensive rats and measuring oxidative stress
markers, including total antioxidation
capacity (TAC), glutathione peroxidase
(GPx) activity, and malondialdehyde
(MDA), have confirmed that oxidative
stress is increased in experimental cere-
bral ischemia (Zhang et al., 2011). This is
in agreement with our previous obser-
vations in spontaneously hypertensive
stroke- prone rats (SHRSP) subjected
to salt load (Napoli et al., 1999), which
causes animal death by acute stroke. In
this study (Napoli et al., 1999) we com-
pared the protective effect of vitamin E to
the dihydropyrine-type CCBs lacidipine
and nifedipine, which are endowed with
antioxidant action. As shown in Figure 1,
rats exposed to high salt diet died from
the 7th week of exposure, so that all ani-
mals were dead after the 10th week. In rats
treated with vitamin E, the death curve
was displaced to the right illustrating the
effect of vitamin E, which reduced mor-
tality. In the groups treated by CCBs there
was no mortality during the 16 weeks
of salt loading observation. Biochemical
and histochemical markers of oxidative
stress were increased by salt load and sim-
ilarly reduced by drug treatments (Napoli
et al., 1999). It is likely that the antiox-
idant action of vitamin E could delay
but not overcome the adverse effects on
survival in this experimental setting, while
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other additional mechanisms discussed
elsewhere (Godfraind, 2005), including
effects on lipid oxidation, are involved in
the protective effect of CCBs.
Experimental studies summarized in
this opinion paper have shown how
antioxidants inactivated reactive oxygen
species allowing reduction of their tissue
deleterious effects. In vivo animal exper-
iments reported above on experimental
stroke illustrated that for a similar reduc-
tion of oxidative stress indicators, the
antioxidant vitamin E and CCBs were
not endowed with identical mortality-
reducing effects (Napoli et al., 1999).
Indeed, vitamin E just delayed mortality
of salt-loaded stroke-prone SHRs when
CCBs treated rats did survive salt load
(Napoli et al., 1999). This indicates that
the protective effect of vitamin E in this
animal experimental set up if not inex-
istent is extremely weak (Napoli et al.,
1999). It could be argued that short- term
animal experiments could not be predic-
tive of therapeutic action in Humans with
long-term use of antioxidants. Therefore
we selected clinical studies of long dura-
tion considering a sufficiently large num-
ber of patients in order to obtain evidence-
based conclusions. Wang et al. reported
results of a meta-analysis (Wang et al.,
2007) designed to obtain a quantita-
tive overview of outcome trials on the
efficacy of amlodipine or angiotensin
receptor blockers (ARBs) in the preven-
tion of stroke and myocardial infarc-
tion. Authors studied amlodipine versus
placebo or other antihypertensive drugs
including ARBs in major multicenter ran-
domized clinical trials (Wang et al., 2007).
The analysis including seven trials with
78,323 randomly assigned patients indi-
cated that CCBs offer the best statistically
significant protection against stroke and
myocardial infarction (Wang et al., 2007).
Furthermore it appeared that some out-
comes were not directly related to reduc-
tion of blood pressure, which supports
an additional beneficial role of CCBs as
antioxidants in stroke and CVD, as sug-
gested elsewhere (Godfraind, 2004). No
doubt that such an action of CCBs may
reduce mortality, but, to date, their antiox-
idant action has not been evaluated in ran-
domized clinical trials. Nevertheless, RCTs
confirmed in humans the protective effect
of CCBs observed in some experimental
animal studies (Napoli et al., 1999). Since
there are no comparative randomized clin-
ical studies comparing CCBs and antiox-
idants, we could only use meta-analyses
including RCTs. Schurks et al. conducted a
meta-analysis on human studies (Schurks
et al., 2010). They included nine ran-
domized controlled trials investigating the
effect on stroke of dietary supplemen-
tation with vitamin E at daily doses
between 50 and 200 mg. From an analysis
involving 118,765 participants the authors
concluded that vitamin E increased the
risk for hemorrhagic stroke by 22% and
reduced the risk of ischemic stroke by 10%.
This differential risk pattern appeared
obscured when looking at the cumula-
tive risk of stroke (Schurks et al., 2010).
Given the relatively small risk reduction
of ischemic stroke and the generally more
severe outcome of hemorrhagic stroke,
author’s conclusion was that indiscrimi-
nate widespread use of vitamin E should
be cautioned against. A Cochrane meta-
analysis (Bjelakovic et al., 2012) stud-
ied the beneficial and harmful effects of
antioxidant supplements for prevention of
mortality in adults. The authors included
all primary and secondary prevention
randomized clinical trials on antioxidant
supplements (beta-carotene, vitamin A,
vitamin C, vitamin E, and selenium) ver-
sus placebo or no intervention (Bjelakovic
et al., 2012). The analysis included 78
randomized trials with 296,707 partici-
pants. The mean age was 63 years and
the mean proportion of women equaled
46%. All antioxidants were administered
orally, either alone or in combination
with vitamins, minerals, or other inter-
ventions. The duration of supplementa-
tion varied with a mean of 3 years and
a median of 2 years. There was no sig-
nificant difference in effect between the
primary prevention and the secondary
prevention trials (Bjelakovic et al., 2012).
In the 56 trials with a low risk of
bias, the antioxidant supplements even
increased mortality, mainly with beta-
carotene and vitamin E (Bjelakovic et al.,
2012). In another publication, data of
this Cochrane meta-analysis were eval-
uated for beta-carotene, vitamin A and
vitamin E, which, for a dose above 15
mg/day, significantly increased mortality
(Bjelakovic et al., 2013). It is notewor-
thy that in AREDS trials it was observed
that antioxidants preparations (see Box 1
in Supplementary Material) reduced the
risk of progression to advanced AMD
(age-related macular degeneration (Age-
Related Eye Disease Study 2 (AREDS2)
Research Group et al., 2013).
In conclusion, at pharmacologically
active concentrations, Vitamin E and
CCBs have a similar effect on markers
of oxidative stress in experimental stud-
ies while corresponding data in humans
are scarce. However, the therapeutic out-
comes are quite different. In randomized
control trials (RCT) CCBs improved car-
diovascular risk (Godfraind, 2014) while,
with exception for AREDS trials, vita-
mins C and E resulted ineffective (Myung
et al., 2013) or, in some situations, even
detrimental (Gale et al., 1995).
Thus, there is currently no evidence
that allows recommending dietary sup-
plementation with antioxidants for the
primary or secondary prevention of
cardiovascular disease.
SUPPLEMENTARY MATERIAL
The Supplementary Material for
this article can be found online at:
http://www.frontiersin.org/journal/10.338
9/fphar.2015.00010/abstract
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